Prima BioMed (NASDAQ:IMMP) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Shares of Prima BioMed Ltd (NASDAQ:IMMP) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.40 and traded as high as $0.4104. Prima BioMed shares last traded at $0.3922, with a volume of 153,277 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wall Street Zen raised Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prima BioMed in a research report on Friday, July 10th. Finally, Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.50.

Prima BioMed Price Performance

The business has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $1.07.

Institutional Trading of Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC increased its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.